Guidant ICD, Stent Tactics Assuage Wall Street; Q1 Index Inches Up
This article was originally published in The Gray Sheet
Executive Summary
Guidant allayed investor uncertainty over its future business strategy by winning a favorable MCAC reimbursement recommendation and executing a string of stent technology acquisitions, propelling the stock ahead 17.3% for the first quarter
You may also be interested in...
Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Heightened corporate interest in innovative drug-delivery technologies offers greater opportunities for small device firms to attract larger company investment, venture capitalists say
Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Heightened corporate interest in innovative drug-delivery technologies offers greater opportunities for small device firms to attract larger company investment, venture capitalists say
DES Makers, Hospitals Will Not Get Higher-Paying DRG In FY 2004 – Scully
Competition provided by additional drug-eluting stent players in the U.S. ultimately will drive down pricing, making it unnecessary to further increase reimbursement for the technology in FY 2004, CMS Administrator Tom Scully asserted